Cost Avoidance of Using an Automatic Therapeutic Interchange of Racemic Albuterol in Place of Levalbuterol
Chad Weinhold, RRT, Pharm.D Candidate 2014
Christopher S Holaway, Pharm.D. Assistant Professor
Georgia Campus - Philadelphia College of Osteopathic Medicine
School of Pharmacy
Suwanee, Georgia

Levalbuterol may be prescribed in place of racemic albuterol to help decrease the adverse effects thought to be mediated by the S-enantiomer in racemic albuterol. Racemic albuterol is a 50:50 mixture of R- and S-enantiomers, whereas levalbuterol is only the R-enantiomer. A review of literature shows conflicting results regarding levalbuterol adverse effects.

An annual drug usage evaluation for levalbuterol 0.625mg and 1.25mg was completed for the time period of January 1, 2012 through January 31, 2013 across all inpatient admissions for a 550 bed not-for-profit regional medical center. The consensus standard of interchange of racemic albuterol for levalbuterol occurs with a 2:1 ratio (e.g. racemic albuterol 2.5mg for levalbuterol 1.25mg and racemic albuterol 1.25mg for levalbuterol 0.625mg). The cost avoidance for this study was calculated using this ratio.

The annual cost avoidance of automatically interchanging racemic albuterol in place of levalbuterol was determined by comparing the purchase costs and usage of levalbuterol 0.625mg and 1.25mg against the purchase costs of racemic albuterol 1.25mg and 2.5mg.

The cost avoidance at interchange rates between 70% through 100% was calculated.

There was a total of 15096 units of levalbuterol 0.625mg used in this time period which yielded an annual spending of $49816. There was a total of 17214 units of levalbuterol 1.25mg used in this time period that yielded an annual spending of $68823. An interchange rate of 70% to 100% could yield a cost avoidance in the range of $71186 to $101695 annually.

An annual drug usage evaluation for levalbuterol 0.625mg and 1.25mg was completed for the time period of January 1, 2012 through January 31, 2013 across all inpatient admissions for a 550 bed not-for-profit regional medical center. The consensus standard of interchange of racemic albuterol for levalbuterol occurs with a 2:1 ratio (e.g. racemic albuterol 2.5mg for levalbuterol 1.25mg and racemic albuterol 1.25mg for levalbuterol 0.625mg). The cost avoidance for this study was calculated using this ratio.

The annual cost avoidance of automatically interchanging racemic albuterol in place of levalbuterol was determined by comparing the purchase costs and usage of levalbuterol 0.625mg and 1.25mg against the purchase costs of racemic albuterol 1.25mg and 2.5mg.

The cost avoidance at interchange rates between 70% through 100% was calculated.

There was a total of 15096 units of levalbuterol 0.625mg used in this time period which yielded an annual spending of $49816. There was a total of 17214 units of levalbuterol 1.25mg used in this time period that yielded an annual spending of $68823. An interchange rate of 70% to 100% could yield a cost avoidance in the range of $71186 to $101695 annually.

Levalbuterol costs 3.5 to 25 times more than racemic albuterol. The range of cost avoidance using an automatic therapeutic interchange of racemic albuterol for levalbuterol can vary. Various health system pharmacies utilize different interchange rates.

The purpose of this retrospective drug usage evaluation was to determine if any cost avoidance would occur by utilizing an automatic therapeutic interchange of racemic albuterol for levalbuterol.

Depending on the annual rate of conversion, the automatic therapeutic interchange of racemic albuterol in place of levalbuterol can yield an annual cost avoidance from $71186 to $101695.

A protocol for automatic therapeutic interchange of racemic albuterol for levalbuterol can offer substantial savings, even at interchange rates of less than 100%.

Northeast Georgia Interdisciplinary Team Members
Melissa Frank, Pharm.D, Clinical Coordinator, Pharmacy
Tracy Berry, RRT, Operations Manager, Respiratory Care
Anthony Alexander, RRT, Director, Respiratory Care